ALVOW
Alvotech
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IS
$0.30
−6.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 492.0M | 586.3M | 489.7M | 91.4M | 83.0M |
| Cost of Revenue | 194.6M | 235.6M | 185.3M | 160.9M | 64.1M |
| Gross Profit | 297.4M | 350.8M | 304.4M | (69.4M) | 18.9M |
| Operating Expenses | |||||
| R&D Expense | 137.7M | 184.2M | 171.3M | 210.8M | 180.6M |
| SG&A Expense | 114.8M | 90.9M | 61.5M | 73.0M | 186.7M |
| General & Admin Expense | 45.6M | 90.9M | 61.5M | 73.0M | 186.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.4M) | (2.6M) | 2.0M | 1.6M | (2.0M) |
| Total Operating Expenses | 250.1M | 272.6M | 234.7M | 285.4M | 365.4M |
| Cost and Expenses | 444.6M | 508.1M | 420.0M | 446.3M | 429.5M |
| Operating Income (EBIT) | 47.3M | 78.2M | 69.6M | (354.9M) | (346.4M) |
| Non-Operating | |||||
| Interest Income | 82.7M | 198.5M | 4.6M | 4.8M | 912.0K |
| Interest Expense | 158.8M | 149.2M | 157.6M | 134.8M | 91.4M |
| Net Interest Income | (76.2M) | 49.3M | (153.0M) | (130.0M) | (90.5M) |
| Other Non-Op Income/Expense | (79.5M) | 58.1M | (287.2M) | (296.2M) | (205.2M) |
| Non-Operating Income (excl Interest) | 82.1M | (207.3M) | 133.2M | 163.0M | 113.8M |
| EBT (Pre-Tax Income) | (32.2M) | 136.3M | (217.6M) | (651.0M) | (551.6M) |
| Income Tax Expense | 147.4M | 108.4M | 14.3M | (99.3M) | (38.1M) |
| Bottom Line | |||||
| Net Income | (179.6M) | 27.9M | (231.9M) | (551.7M) | (513.6M) |
| Earnings from Cont. Ops | (179.6M) | 27.9M | (231.9M) | (551.7M) | (513.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (179.6M) | 27.9M | (231.9M) | (551.7M) | (513.6M) |
| Per Share | |||||
| Basic EPS | ($0.58) | $0.10 | ($0.87) | ($2.43) | ($2.60) |
| Diluted EPS | ($0.63) | $0.10 | ($0.87) | ($2.43) | ($2.60) |
| Revenue Per Share | $1.38 | $2.10 | $1.83 | $0.40 | $0.42 |
| Shares | |||||
| Basic Shares Outstanding | 356.8M | 279.2M | 267.9M | 227.3M | 197.7M |
| Diluted Shares Outstanding | 356.8M | 279.2M | 267.9M | 227.3M | 197.7M |
| Profitability Metrics | |||||
| EBITDA | (1.4M) | 323.4M | (32.3M) | (493.7M) | (439.8M) |
| D&A | 33.4M | 37.9M | 31.3M | 24.2M | 20.4M |
| EBIT | (34.8M) | 285.5M | (63.6M) | (517.9M) | (460.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026